Published in AIDS Weekly, August 18th, 1997
Earlier in 1997, Ivax and NaPro BioTherapeutics, Inc. submitted a New Drug Application to the FDA seeking approval to manufacture and market Paxene in the United States for the treatment of KS, an important cancer related to the immunocompromised state that accompanies AIDS. Ivax has applied for exclusivity under the Orphan Drug Act. Paxene is Ivax's registered trade name for the compound paclitaxel (also called taxol).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.